Abstract
Purpose: This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. Methods: Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle. Results: Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all values statistically significant, P ≤ 0.001). Irofulven also produced a statistically significant (P ≤ 0.001) increase in the median survival of mice bearing D-456 intracranial xenografts with a 162% increase in median survival. Conclusions: Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evaluation in patients with this neoplasm is warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 413-416 |
Number of pages | 4 |
Journal | Cancer chemotherapy and pharmacology |
Volume | 48 |
Issue number | 5 |
DOIs | |
State | Published - 2001 |
Externally published | Yes |
Keywords
- CNS tumors
- Glioblastoma multiforme
- Irofulven
- Nude mice
- Xenografts
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
- Cancer Research
- Toxicology
- Pharmacology